Public Companies
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30,…
- Cash and cash equivalents of $117.7 million by Sept. 30, a 17.2% decrease from the $142.1 million held by Dec. 31, 2022 and a quarterly mild 0.6% increase ($116.9 million held by June 30, 2023.)
- Nine-month net cash for operating activities totaled $43.8 million, a 17.4% increase as of the $37.3 million used in the same period in 2022.
- Quarterly R&D expenses of $13.2 million, a 69.2% increase as of the $7.8 million of the same quarter in 2022.
- Quarterly general and administrative (G&A) expenses of $8.4 million, an 8.7% decrease as of the $9.2 million of the same quarter in 2022.
- Quarterly net loss of $17.9 million, an almost 8.5% increase considering the $16.5 million net loss during the same period in 2022.
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week agoCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin5 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID